Skip to content
Clinical Trials – home
BulgariaBack to Bulgaria

Clinical trials in Gabrovo – page 18

234 clinical trials in Gabrovo, Bulgaria across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Gabrovo at a glance
234
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

234 trials in Gabrovo

Open in trial search

Bipolar disorder

Not recruiting

Study on Lumateperone for Treating Manic Episodes in Bipolar I Disorder Patients

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Lumateperone
  • Sponsor:Intra-Cellular Therapies Inc.

Asthma

Not recruiting

Study on the Effectiveness and Safety of Budesonide, Glycopyrronium, and Formoterol Inhaler for Adults and Adolescents with Severe Asthma Not Well Controlled

Registered drug
Countries:BulgariaBulgaria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Budesonide
  • Sponsor:AstraZeneca AB

Title: Comparison of oral tebipenem pivoxil versus intravenous imipenem-cilastatin in adults with complicated urinary tract infection or acute pyelonephritis

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Cilastatin
  • Sponsor:Spero Therapeutics Inc.

Cardiac failure

Not recruiting

Study of XXB750 and Drug Combination for Patients with Heart Failure

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Azilsartan Medoxomil
  • Sponsor:Novartis Pharma AG

Schizophrenia

Not recruiting

Study on Valbenazine for Patients with Schizophrenia Not Responding Well to Antipsychotic Treatment

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Valbenazine Ditosylate
  • Sponsor:Neurocrine Biosciences Inc.

Study on the Effectiveness and Safety of Litifilimab for Patients with Active Subacute or Chronic Cutaneous Lupus Erythematosus Resistant to Antimalarial Therapy

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Litifilimab
  • Sponsor:Biogen Idec Research Limited

Colorectal cancer

Not recruiting

Study for Patients with Metastatic Colorectal Cancer with BRAF V600E Mutation Using Encorafenib, Cetuximab, and Chemotherapy Combination

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Pfizer Inc.

Study on the Effectiveness and Safety of Finerenone for Adults with Non-Diabetic Chronic Kidney Disease

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Finerenone
  • Sponsor:Bayer AG

Dermatitis atopic

Not recruiting

Study on Amlitelimab for Patients Aged 12 and Older with Moderate-to-Severe Atopic Dermatitis

Registered drug
Countries:BulgariaBulgaria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Amlitelimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study on Long-Term Safety of Itepekimab for Patients with Chronic Obstructive Pulmonary Disease (COPD)

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Itepekimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study Comparing RBS-001 and Aflibercept for Patients with Neovascular Age-Related Macular Degeneration

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Rophibio Inc.

Study on the Safety and Effectiveness of Tovinontrine for Adults with Chronic Heart Failure with Reduced Ejection Fraction

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Tovinontrine
  • Sponsor:Cardurion Pharmaceuticals Inc.

Other cities in Bulgaria

The busiest research cities in the country

All 52 cities in Bulgaria

Clinical research in Gabrovo

What the registry says about research in the country

01 Oncology Research

Innovative trials focusing on advanced cancer treatments, including studies for breast cancer, prostate cancer, lung cancer, and bladder cancer. Research encompasses both targeted therapies and combination treatments.

  • Metastatic breast cancer treatments
  • Advanced non-small cell lung cancer therapies
  • Prostate cancer interventions
  • Bladder cancer treatments

Special emphasis on developing targeted therapies for specific genetic mutations and combinations with immunotherapy.

02 Respiratory Medicine

Comprehensive research into respiratory conditions, with particular focus on chronic diseases and their management through innovative therapeutic approaches.

  • Asthma management studies
  • COPD treatment evaluations
  • Maintenance therapy optimization

Trials evaluate both single and combination therapies for improving lung function and quality of life.

03 Dermatology Studies

Advanced research in chronic skin conditions, investigating new therapeutic options for various dermatological disorders.

  • Plaque psoriasis treatments
  • Atopic dermatitis therapies
  • Long-term safety evaluations

Focus on developing both topical and systemic treatments for moderate to severe cases.

04 Cardiovascular Research

Innovative studies addressing heart conditions and related metabolic disorders, including new approaches to managing cholesterol and heart failure.

  • Heart failure treatments
  • Cholesterol management
  • Hypertriglyceridemia therapies

Emphasis on both preserved and reduced ejection fraction heart failure treatments.

05 Infectious Diseases

Research focusing on viral infections and preventive medicine, including vaccine development and infection management.

  • Influenza vaccine studies
  • Varicella vaccination
  • Urinary tract infection treatments

Special attention to vaccine safety and efficacy in various age groups.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.